BiotechTube

lufepirsen high dose + Vehicle + lufepirsen low dose

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Persistent Corneal Epithelial Defect

Conditions

Persistent Corneal Epithelial Defect

Trial Timeline

Aug 17, 2023 → Dec 1, 2025

NCT ID
NCT05966493

About lufepirsen high dose + Vehicle + lufepirsen low dose

lufepirsen high dose + Vehicle + lufepirsen low dose is a phase 2 stage product being developed by Glaukos for Persistent Corneal Epithelial Defect. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05966493. Target conditions include Persistent Corneal Epithelial Defect.

What happened to similar drugs?

4 of 8 similar drugs in Persistent Corneal Epithelial Defect were approved

Approved (4) Terminated (1) Active (4)
✅Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + PlaceboNovartisApproved
✅RivastigmineNovartisApproved
✅Omalizumab + PlaceboNovartisApproved
✅irbesartan + placeboSanofiApproved
🔄E7777 9 mcg/kgEisaiPhase 3
🔄CertoparinNovartisPhase 3
🔄Omalizumab + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05966493Phase 2Recruiting

Competing Products

20 competing products in Persistent Corneal Epithelial Defect

See all competitors
ProductCompanyStageHype Score
E7777 9 mcg/kgEisaiPhase 3
40
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
35
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment EAstraZenecaPhase 1
29
AZD0837 + VKA INR 2-3AstraZenecaPhase 2
35
AZD0837 + AspirinAstraZenecaPhase 2
35
Montelukast to placebo + Placebo to montelukastMerckPre-clinical
26
Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone AcetateNovartisPhase 2
35
Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + PlaceboNovartisApproved
35
CertoparinNovartisPhase 3
40
Omalizumab + PlaceboNovartisPhase 3
40
RivastigmineNovartisApproved
43
QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 daysNovartisPhase 2
35
Indacaterol + Placebo to IndacaterolNovartisPhase 2
35
Omalizumab + PlaceboNovartisApproved
43
placebo + iv sildenafilPfizerPhase 3
40
etanercept + placeboPfizerPhase 2
35
SildenafilPfizerPhase 2
27
irbesartan + placeboSanofiApproved
39
iloprostBayerPre-clinical
15
IV Remodulin + PlaceboUnited TherapeuticsPhase 2
24